This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Raclopride
- DrugBank Accession Number
- DB12518
- Background
Raclopride has been used in trials studying Parkinson Disease.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Raclopride (DB12518)
- Weight
- Average: 347.24
Monoisotopic: 346.0850979 - Chemical Formula
- C15H20Cl2N2O3
- Synonyms
- Racloprida
- Raclopride
- Raclopridum
- External IDs
- FLA 870
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UDopamine D2 receptor antagonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when Raclopride is combined with 1,2-Benzodiazepine. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Raclopride. Acetophenazine The risk or severity of adverse effects can be increased when Acetophenazine is combined with Raclopride. Agomelatine The risk or severity of adverse effects can be increased when Agomelatine is combined with Raclopride. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Raclopride. Alimemazine The risk or severity of adverse effects can be increased when Alimemazine is combined with Raclopride. Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Raclopride. Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Raclopride. Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Raclopride. Alverine The risk or severity of adverse effects can be increased when Alverine is combined with Raclopride. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Acids, Carbocyclic
- Amides
- Antipsychotic Agents
- Benzamides and benzamide derivatives
- Benzene Derivatives
- Benzoates
- Central Nervous System Agents
- Central Nervous System Depressants
- Chlorobenzoates
- Dopamine Agents
- Dopamine Antagonists
- Dopamine D2 Receptor Antagonists
- Neurotoxic agents
- Neurotransmitter Agents
- Psychotropic Drugs
- Tranquilizing Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Salicylamides
- Alternative Parents
- Methoxyphenols / 3-halobenzoic acids and derivatives / Benzamides / Benzoyl derivatives / Dichlorobenzenes / Anisoles / Methoxybenzenes / O-chlorophenols / P-chlorophenols / Phenoxy compounds show 12 more
- Substituents
- 1,3-dichlorobenzene / 2-chlorophenol / 2-halophenol / 3-halobenzoic acid or derivatives / 4-chlorophenol / 4-halophenol / Alkyl aryl ether / Amine / Amino acid or derivatives / Anisole show 34 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 430K3SOZ7G
- CAS number
- 84225-95-6
- InChI Key
- WAOQONBSWFLFPE-VIFPVBQESA-N
- InChI
- InChI=1S/C15H20Cl2N2O3/c1-3-19-6-4-5-9(19)8-18-15(21)12-13(20)10(16)7-11(17)14(12)22-2/h7,9,20H,3-6,8H2,1-2H3,(H,18,21)/t9-/m0/s1
- IUPAC Name
- 3,5-dichloro-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2-hydroxy-6-methoxybenzamide
- SMILES
- CCN1CCC[C@H]1CNC(=O)C1=C(O)C(Cl)=CC(Cl)=C1OC
References
- General References
- Not Available
- External Links
- PubChem Compound
- 3033769
- PubChem Substance
- 347828748
- ChemSpider
- 2298373
- BindingDB
- 50005118
- ChEBI
- 92070
- ChEMBL
- CHEMBL8809
- ZINC
- ZINC000025757754
- Wikipedia
- Raclopride
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Basic Science Eating Disorders 1 4 Recruiting Treatment Anhedonia / Depression / Psychosis 1 1 Completed Basic Science Depression 1 0 Active Not Recruiting Basic Science BMI >27 kg/m2 / Healthy Subjects (HS) / Obesity 1 0 Recruiting Basic Science Normal Physiology / Opioid Use Disorder (OUD) 1 Not Available Completed Not Available Healthy Subjects (HS) / Parkinson's Disease (PD) 1 Not Available Recruiting Basic Science Traumatic Brain Injury (TBI) 1 Not Available Withdrawn Not Available Schizophrenia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.126 mg/mL ALOGPS logP 3.19 ALOGPS logP 2 Chemaxon logS -3.4 ALOGPS pKa (Strongest Acidic) 6.26 Chemaxon pKa (Strongest Basic) 8.47 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 61.8 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 88.07 m3·mol-1 Chemaxon Polarizability 35.02 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-0002-0119000000-60d7b9266bbc9f46e57c
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Potassium channel regulator activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
- Gene Name
- DRD2
- Uniprot ID
- P14416
- Uniprot Name
- D(2) dopamine receptor
- Molecular Weight
- 50618.91 Da
References
- Martinez D, Broft A, Foltin RW, Slifstein M, Hwang DR, Huang Y, Perez A, Frankle WG, Cooper T, Kleber HD, Fischman MW, Laruelle M: Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology. 2004 Jun;29(6):1190-202. [Article]
Drug created at October 20, 2016 22:41 / Updated at February 21, 2021 18:53